Is prostate cancer screening justified in the bedouin population?

Onkologie

Volumn 32, Issue 5, 2009, Pages 260-262

  Abdallah, Mashal ^a   Lazarev, Irina ^a   Ariad, Samuel ^a   Mermershtain, Wilmosh ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Bedouin population; Prostate cancer; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARAB; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CHRONIC INFLAMMATION; CHRONIC PROSTATITIS; CONCENTRATION (PARAMETERS); DESERT; DIGITAL RECTAL EXAMINATION; GEOGRAPHIC DISTRIBUTION; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY;

EID: 67549114975     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kishor M, Cable G: Meta-analysis of prostaticspecific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003;16:95-101.
2. Hoogendam A, Buntix F, deVet HCW: The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam Pract 1999;16:621-626.
3. Schwartz K, Deschere B, Xu J: Screening for prostate cancer: who and how often? J Fam Pract 2005;54: 586-596.
4. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-294.
5. Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, Knekt I: Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol 2001;166:2189-2191.
6. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM: Serum prostate- specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860-864.
7. Baade PD, Youlden DR, Krnjacki LJ: International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009;53:171-184.
8. Taha SA, Kamal BA: Screening program for prostate cancer at a university hospital in eastern Saudi Arabia. Saudi Med J 2005;26:1104-1106.
9. Kehinde EO, Akanji AO, Mojiminiyi OA, Bashir AA, Daar AS, Varghese R: Putative role of serum nsuline-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men. Prostate Cancer Prostatic Dis 2005;8:84-90.
10. Friedman J, Yaniv Z, Dafni A, Palewitch D: A preliminary classification of the healing potential of medical plants, based on a rational analysis of an ethnopharmacological field survey among Bedouins in the Negev Desert, Israel. J Ethnopharmacol 1986;16:275-287.
11. Ali-Shtayeh MS, Yaniv Z, Mahajna J: Ethnobotanical survey in the Palestinian area: a classification of the healing potential of medicinal plants. J Ethnopharmacol 2000;73:221-232.
12. Fosså SD, Eri LM, Skovlund E, Tveter K, Vatten L; Norwegian Urological Cancer Group: No randomised trial of prostate-cancer screening in Norway. Lancet Oncol 2001;2:741-745.
13. Frankel S, Smith GD, Donovan J, Neal D: Screening for prostate cancer. Lancet 2003;361:1122-1128.